Key result
Bedtime administration of guanabenz reduced morning blood pressure and led to the resolution of left ventricular hypertrophy in 82.4% of treated patients.
Why the study?
Does guanabenz reduce morning blood pressure and prevent progression of chronic renal insufficiency and LVH in patients with morning hypertension?
RCT (n=34)
random
Does guanabenz reduce morning blood pressure and prevent progression of chronic renal insufficiency and LVH in patients with morning hypertension?
Targeting morning hypertension with bedtime guanabenz in patients with chronic renal insufficiency and LVH reduces morning blood pressure, resolves LVH, and slows nephropathy progression.
Answers are grounded in this paper and cite their sources.
Morning self-monitored BP may flag renal progression and LVH risk in CKD; leaves open whether targeting it alters outcomes.
Self-monitoring values of blood pressure may better reflect the average long-term blood pressure value than sporadic measurements in the physician's office and be more useful for blood pressure control. In the present study, we compared the results of self-monitoring of blood pressure values, especially in the morning, with office blood pressure, and related these to progression of chronic renal insufficiency and left ventricular hypertrophy (LVH). Thirty-four patients were selected from 316 subjects with chronic renal insufficiency (average serum creatinine 1.72 +/- 0.15 mg/dl, mean age 52.6 +/- 3.5 yrs) in accordance with the following criteria (1) office blood pressure was less than 140/90 mmHg, (2) blood pressure was controlled with amlodipine (5-20 mg/day) combined with benazepril (2.5 mg/day), (3) morning blood pressure was greater than 150/90 mmHg at 6-9 AM and (4) LVH had been determined by echocardiography (posterior wall thickness; PWT > or = 12 mm). The patients were assigned to 2 groups at random and were given: (1) guanabenz (GB; 2-8 mg at I I PM, n = 17) or (2) placebo (n = 17). Two years later, the average blood pressure of both groups as measured in the office was not significantly different: however, BP in the morning was significantly reduced from 158 +/- 6 to 134 +/- 4 mmHg in GB treated group (P< 0.001). In 14 of 17 patients in GB treated group, LVH resolved and there was only mild progression of nephropathy (serum creatinine: 1.69 +/- 0.18 to 1.81 +/- 0.19 mg/dl). In 12 of 14 patients in placebo group, whose morning blood pressure remained at greater than 150/90 mmHg, LVH was retained and there was moderate progression of nephropathy (serum creatinine: 1.73 +/- 0.14 to 2.62 +/- 0.50mg/dl). From these results, it is suggested that antihypertensive treatment with combination therapy based on self-monitoring BP is cardio-renoprotective in patients with chronic renal insufficiency and LVH.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2002) conducted an RCT in Chronic renal insufficiency and left ventricular hypertrophy (n=34). Guanabenz vs. Placebo was evaluated on Resolution of left ventricular hypertrophy. Bedtime administration of guanabenz reduced morning blood pressure and led to the resolution of left ventricular hypertrophy in 82.4% of treated patients.
Synapse has enriched 10 related papers. Consider them for comparative context: